Zavzpret
Drug name: Zavzpret | Dosage form: Nasal spray (intranasal; 10 mg) | Approval year: 2023 | Company: Pfizer Laboratories, Div Pfizer Inc., New York, NY | Class: Calcitonin gene-related peptide receptor antagonists | System:
Indications
- Indicated for the acute treatment of migraine with or without aura in adults.
Document title: Zavegepant for Acute Treatment of Migraine: A Systematic Review and Meta-analysis of Randomized Controlled Trials Document link: https://journals.lww.com/clinicalneuropharm/abstract/2024/05000/zavegepant_for_acute_treatment_of_migraine__a.3.aspx Document source: Clinical Neuropharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2024
Document title: Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials Document link: https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-024-01723-4 Document source: The Journal of Headache and Pain Document type: Systematic Reviews / Meta-Analyses Document year: 2024
Document title: Zavegepant nasal spray for the acute treatment of migraine: A meta analysis Document link: https://journals.lww.com/md-journal/fulltext/2023/10270/zavegepant_nasal_spray_for_the_acute_treatment_of.118.aspx Document source: Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2023
Document title: Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506288/pdf/10194_2023_Article_1662.pdf Document source: The Journal of Headache and Pain Document type: Systematic Reviews / Meta-Analyses Document year: 2023
Document title: Safety and Efficacy of Zavegepant in Treating Migraine: A Systematic Review Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428082/pdf/cureus-0015-00000041991.pdf Document source: Cureus Document type: Systematic Reviews / Meta-Analyses Document year: 2023
Document title: Zavzpret (zavegepant) Prescribing Information. Document link: https://labeling.pfizer.com/ShowLabeling.aspx?id=19471 Document source: Pfizer Laboratories, Div Pfizer Inc., New York, NY Document type: Product Monograph / Prescribing Information Document year: 2023
Qulipta
Drug name: Qulipta | Dosage form: Tablet (oral; 10 mg, 30 mg, 60 mg) | Approval year: 2021 | Company: AbbVie Inc., North Chicago, IL | Class: Calcitonin gene-related peptide receptor antagonists | System:
Indications
- Indicated for the preventive treatment of migraine in adults.
Document title: Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264921/pdf/10194_2024_Article_1822.pdf Document source: The Journal of Headache and Pain Document type: Systematic Reviews / Meta-Analyses Document year: 2024
Document title: Comparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine Prevention: A Network Meta-analysis Document link: https://journals.lww.com/clinicalpain/abstract/2023/10000/comparative_efficacy_and_safety_of_five.7.aspx Document source: The Clinical Journal of Pain Document type: Systematic Reviews / Meta-Analyses Document year: 2023
Document title: Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials Document link: https://journals.sagepub.com/doi/10.1177/03331024231159366 Document source: Cephalalgia Document type: Systematic Reviews / Meta-Analyses Document year: 2023
Document title: Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis Document link: https://journals.sagepub.com/doi/full/10.1177/03331024231152169?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org Document source: Cephalalgia Document type: Systematic Reviews / Meta-Analyses Document year: 2023
Document title: Qulipta (atogepant) Prescribing Information. Document link: https://www.rxabbvie.com/pdf/QULIPTA_pi.pdf Document source: AbbVie Inc., North Chicago, IL Document type: Product Monograph / Prescribing Information Document year: 2023
Document title: Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338214/pdf/40120_2022_Article_370.pdf Document source: Neurology and Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2022
Document title: The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903713/pdf/10194_2022_Article_1391.pdf Document source: The Journal of Headache and Pain Document type: Systematic Reviews / Meta-Analyses Document year: 2022
Nurtec odt
Drug name: Nurtec ODT | Dosage form: Tablet (oral; 75 mg) | Approval year: 2020 | Company: Pfizer Inc., New York, NY | Class: Calcitonin gene-related peptide receptor antagonists | System: Nervous
Indications
- Indicated for the acute treatment of migraine with or without aura in adults
- Indicated for the treatment of episodic migraine in adults.
Document title: Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10840250/pdf/10194_2024_Article_1723.pdf Document source: The Journal of Headache and Pain Document type: Systematic Reviews / Meta-Analyses Document year: 2024
Document title: Clinical efficacy and safety of rimegepant in the treatment of migraine: a meta-analysis of randomized controlled trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318539/pdf/fneur-14-1205778.pdf Document source: Frontiers in Neurology Document type: Systematic Reviews / Meta-Analyses Document year: 2023
Document title: Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis Document link: https://journals.sagepub.com/doi/reader/10.1177/03331024231152169 Document source: Cephalalgia Document type: Systematic Reviews / Meta-Analyses Document year: 2023
Document title: Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature Document link: https://journals.sagepub.com/doi/reader/10.1177/03331024231151419 Document source: Cephalalgia Document type: Systematic Reviews / Meta-Analyses Document year: 2023
Document title: Nurtec ODT (rimegepant) Prescribing Information. Document link: https://labeling.pfizer.com/ShowLabeling.aspx?id=19036 Document source: Pfizer Inc., New York, NY Document type: Product Monograph / Prescribing Information Document year: 2023
Document title: Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm Document link: https://ncbi.nlm.nih.gov/pmc/articles/PMC9555761/pdf/ajp-38-680.pdf Document source: The Clinical Journal of Pain Document type: Systematic Reviews / Meta-Analyses Document year: 2022
Document title: Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258126/pdf/10194_2022_Article_1440.pdf Document source: The Journal of Headache and Pain Document type: Systematic Reviews / Meta-Analyses Document year: 2022
Document title: Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis Document link: https://www.tandfonline.com/doi/epdf/10.1080/14737167.2021.1945444?needAccess=true Document source: Expert Review of Pharmacoeconomics & Outcomes Research Document type: Systematic Reviews / Meta-Analyses Document year: 2022
Document title: Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506232/?report=printable Document source: JAMA Network Open Document type: Systematic Reviews / Meta-Analyses Document year: 2021
Document title: Ditans vs Gepants: A Systematic Review and Indirect Network Meta-Analysis for Comparative Analysis of Efficacy and Safety Document link: https://journals.lww.com/neur/fulltext/2021/69001/ditans_vs_gepants__a_systematic_review_and.6.aspx Document source: Neurology India Document type: Systematic Reviews / Meta-Analyses Document year: 2021
Document title: The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Document link: https://headachejournal.onlinelibrary.wiley.com/doi/epdf/10.1111/head.14153 Document source: Headache Document type: Clinical Practice Guidelines Document year: 2021
Document title: Gepants for abortive treatment of migraine: A network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428487/pdf/BRB3-10-e01701.pdf Document source: Brain and Behavior Document type: Systematic Reviews / Meta-Analyses Document year: 2020
Document title: VA/DoD clinical practice guidelines: the primary care management of headache. Document link: https://www.healthquality.va.gov/guidelines/pain/headache/VADoDHeadacheCPGProviderSummaryFinal508v2.pdf Document source: U.S Department of Veteran Affairs Document type: Clinical Practice Guidelines Document year: 2020
Document title: Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992660/pdf/fphar-10-01577.pdf Document source: Frontiers in Pharmacology Document type: Systematic Reviews / Meta-Analyses Document year: 2019
Ubrelvy
Drug name: Ubrelvy | Dosage form: Tablet (oral; 50 mg, 100 mg) | Approval year: 2019 | Company: AbbVie Inc., North Chicago, IL | Class: Calcitonin gene-related peptide receptor antagonists | System: Nervous
Indications
- Indicated for the acute treatment of migraine with or without aura in adults.
Document title: Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11409395/?report=printable Document source: BMJ (Clinical Research Ed.) Document type: Systematic Reviews / Meta-Analyses Document year: 2024
Document title: Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10840250/pdf/10194_2024_Article_1723.pdf Document source: The Journal of Headache and Pain Document type: Systematic Reviews / Meta-Analyses Document year: 2024
Document title: Efficacy and safety of ubrogepant for migraine: a meta-analysis of randomized controlled studies Document link: https://www.tandfonline.com/doi/full/10.1080/00207454.2022.2090351 Document source: The International Journal of Neuroscience Document type: Systematic Reviews / Meta-Analyses Document year: 2024
Document title: Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature Document link: https://journals.sagepub.com/doi/reader/10.1177/03331024231151419 Document source: Cephalalgia Document type: Systematic Reviews / Meta-Analyses Document year: 2023
Document title: Ubrelvy (ubrogepant) Prescribing Information. Document link: https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf Document source: AbbVie Inc., North Chicago, IL Document type: Product Monograph / Prescribing Information Document year: 2023
Document title: Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555761/pdf/ajp-38-680.pdf Document source: The Clinical Journal of Pain Document type: Systematic Reviews / Meta-Analyses Document year: 2022
Document title: Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258126/pdf/10194_2022_Article_1440.pdf Document source: The Journal of Headache and Pain Document type: Systematic Reviews / Meta-Analyses Document year: 2022
Document title: Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799553/pdf/12325_2021_Article_1923.pdf Document source: Advances in Therapy Document type: Systematic Reviews / Meta-Analyses Document year: 2022
Document title: Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis Document link: https://www.tandfonline.com/doi/epdf/10.1080/14737167.2021.1945444?needAccess=true Document source: Expert Review of Pharmacoeconomics & Outcomes Research Document type: Systematic Reviews / Meta-Analyses Document year: 2022
Document title: Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506232/?report=printable Document source: JAMA Network Open Document type: Systematic Reviews / Meta-Analyses Document year: 2021
Document title: Ditans vs Gepants: A Systematic Review and Indirect Network Meta-Analysis for Comparative Analysis of Efficacy and Safety Document link: https://journals.lww.com/neur/fulltext/2021/69001/ditans_vs_gepants__a_systematic_review_and.6.aspx Document source: Neurology India, 69(Supplement) Document type: Systematic Reviews / Meta-Analyses Document year: 2021
Document title: Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909234/pdf/medi-100-e24741.pdf Document source: Medicine Document type: Systematic Reviews / Meta-Analyses Document year: 2021
Document title: The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Document link: https://headachejournal.onlinelibrary.wiley.com/doi/epdf/10.1111/head.14153 Document source: Headache Document type: Clinical Practice Guidelines Document year: 2021
Document title: Gepants for abortive treatment of migraine: A network meta-analysis Document link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428487/pdf/BRB3-10-e01701.pdf Document source: Brain and Behavior Document type: Systematic Reviews / Meta-Analyses Document year: 2020